Literature DB >> 11765186

Extraordinarily elevated CA19-9 in benign conditions: a case report and review of the literature.

M Akdoğan1, N Saşmaz, B Kayhan, I Biyikoğlu, S Dişibeyaz, B Sahin.   

Abstract

Carbohydrate antigen CA19-9 is commonly used in the diagnosis of pancreatic and biliary malignancies. However, increases in its level in benign conditions such as acute cholangitis or pancreatitis have also been reported. A 79-year-old woman presented with cholangitis and a pancreatic pseudocyst while showing elevation of CA19-9 up to 35,500 U/mL. The patient was adequately treated and at two months' follow-up the CA19-9 level had returned to normal.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11765186     DOI: 10.1177/030089160108700513

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  23 in total

1.  Pancreato-biliary malignancy diagnosed by endoscopic ultrasonography in absence of a mass lesion on transabdominal imaging: prevalence and predictors.

Authors:  Savio C Reddymasu; Neil Gupta; Shailender Singh; Melissa Oropeza-Vail; Syed Faisal Jafri; Mojtaba Olyaee
Journal:  Dig Dis Sci       Date:  2010-12-28       Impact factor: 3.199

2.  CA 19-9 to rule out pancreatic or biliary cancer among patients with cholestasis: an unsuitable test?

Authors:  Salvatore Madonia; Emma Aragona; Simonetta Maisano; Luigi Montalbano; Mirko Olivo; Francesca Rossi; Gaetano Restivo; Mario Cottone
Journal:  Dig Dis Sci       Date:  2007-03-07       Impact factor: 3.199

3.  [CA 19-9 in the differential diagnosis of pancreatic lesions].

Authors:  S Stintzing; C Herold; E G Hahn; F Boxberger
Journal:  Internist (Berl)       Date:  2008-02       Impact factor: 0.743

Review 4.  Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment.

Authors:  Boris Blechacz; Gregory J Gores
Journal:  Hepatology       Date:  2008-07       Impact factor: 17.425

Review 5.  Cholangiocarcinoma: epidemiology, risk factors, pathogenesis, and diagnosis.

Authors:  Halim Charbel; Firas H Al-Kawas
Journal:  Curr Gastroenterol Rep       Date:  2011-04

6.  Elevated serum level of carbohydrate antigen 19-9 in benign biliary stricture diseases can reduce its value as a tumor marker.

Authors:  Mao-Song Lin; Jun-Xing Huang; Hong Yu
Journal:  Int J Clin Exp Med       Date:  2014-03-15

7.  CA 19-9 in pancreatic cancer: retrospective evaluation of patients with suspicion of pancreatic cancer.

Authors:  Victor Molina; Laura Visa; Carles Conill; Salvador Navarro; Jose M Escudero; Jose M Auge; Xavier Filella; Miguel A Lopez-Boado; Joana Ferrer; Laureano Fernandez-Cruz; Rafael Molina
Journal:  Tumour Biol       Date:  2011-12-29

8.  High expression of S100A11 in pancreatic adenocarcinoma is an unfavorable prognostic marker.

Authors:  Ming-Bing Xiao; Feng Jiang; Wen-Kai Ni; Bu-You Chen; Cui-Hua Lu; Xiao-Yan Li; Run-Zhou Ni
Journal:  Med Oncol       Date:  2011-09-13       Impact factor: 3.064

9.  Increased serum levels of carbohydrate antigen 19-9 and outcomes in primary sclerosing cholangitis patients without cholangiocarcinoma.

Authors:  Preethi G K Venkatesh; Udayakumar Navaneethan; Bo Shen; Arthur J McCullough
Journal:  Dig Dis Sci       Date:  2012-09-25       Impact factor: 3.199

10.  Adjusting CA19-9 values to predict malignancy in obstructive jaundice: influence of bilirubin and C-reactive protein.

Authors:  Gaetano La Greca; Maria Sofia; Rosario Lombardo; Saverio Latteri; Agostino Ricotta; Stefano Puleo; Domenico Russello
Journal:  World J Gastroenterol       Date:  2012-08-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.